Seema Pai, President of the Indian Society for Clinical Research (ISCR), highlighted how digital tools AI, real-world evidence platforms, eConsent, remote monitoring, and decentralized trial models are fundamentally transforming clinical research in India. Speaking at a recent industry forum, she emphasized faster recruitment, improved data quality, greater patient access, and regulatory alignment as key benefits driving India’s rise as a global clinical research hub.
Glimpse:
In her address, Seema Pai noted that digital innovation has reduced trial timelines, enhanced diversity in participant pools, enabled real-time data insights, and strengthened compliance with global standards. Tools like electronic data capture (EDC), AI for site selection and risk-based monitoring, telemedicine visits, and blockchain for data integrity are now mainstream in Indian trials. She stressed that continued collaboration between sponsors, CROs, regulators, and tech providers will be crucial to fully realize the potential of digital-first clinical research in India.
Seema Pai, President of the Indian Society for Clinical Research (ISCR), recently shared her perspective on the profound impact of digital innovation on clinical research in India. Speaking at a high-profile industry event, she described how the convergence of technology and regulatory support is positioning India as one of the fastest-growing and most attractive destinations for global clinical trials.
Key points from her address include:
Accelerated trial timelines and efficiency Digital platforms for patient recruitment (social media targeting, EHR mining), eConsent, and remote ePRO/eCOA have significantly shortened startup and enrollment phases. Improved patient access and diversity Decentralized and hybrid trial models, supported by telemedicine and mobile health apps, are bringing trials closer to underserved populations, including rural and semi-urban communities. Enhanced data quality and real-time insights AI-driven risk-based monitoring, centralized statistical monitoring, and real-world evidence generation are enabling proactive quality management and faster decision-making.
Regulatory momentum Alignment with global standards (ICH E6 R3, FDA digital health guidance) and CDSCO’s progressive policies on digital tools have reduced barriers to adoption. Future outlook Seema Pai called for stronger industry-academia-regulator collaboration, investment in data literacy for investigators, and ethical frameworks for AI use to sustain momentum and maintain India’s reputation for high-quality research.
She also highlighted success stories from Indian sites and sponsors adopting digital solutions, which have led to higher retention rates, lower protocol deviations, and quicker database locks. With India now ranking among the top 10 countries for clinical trial activity, digital innovation is seen as a major catalyst for continued growth.
The ISCR president concluded by urging stakeholders to treat digital transformation not as an optional add-on, but as a core strategy for building a more inclusive, efficient, and patient-centric clinical research ecosystem in India.
“Digital innovation is no longer a nice-to-have it is reshaping how clinical research is designed, conducted, and delivered in India, making it faster, more inclusive, and more impactful.”
By
HB Team
